GLP-1 for Weight Loss: How It Works, Results, and What to Expect

In 2021 the FDA approved the first high-dose semaglutide formulation for chronic weight management, and the category has since expanded to include multiple agents producing average body-weight reductions of roughly 15 to 22 percent over about 68 to 72 weeks in clinical trials. GLP-1 weight loss medications work by activating glucagon-like peptide-1 receptors in the brain and gut, reducing appetite and slowing gastric emptying so patients feel satisfied on less food. These are prescription-only medicines, and understanding how they work — what results are realistic, what the trade-offs are, and why the decision and the dose belong to your prescriber — is essential before starting therapy. For broader context on medical weight-loss approaches, see our wellness guide.

What GLP-1 Actually Does

Glucagon-like peptide-1 is a hormone your small intestine releases when you eat. It signals the pancreas to secrete insulin, the stomach to slow emptying, and — most importantly for weight — the brain to reduce appetite and food intake. Naturally produced GLP-1 is degraded within minutes. GLP-1 receptor-agonist medications are engineered to resist that degradation, allowing once-weekly or daily dosing with prolonged appetite-suppressing effects.

On a GLP-1 drug, people generally notice earlier satiety, reduced hunger between meals, and less interest in high-fat or high-sugar foods. Many describe a fading of “food noise” — the background mental chatter about eating. Combined with slowed stomach emptying, these effects create consistent calorie reduction without deliberate restriction.

Which Drugs Are in the GLP-1 Class

Several medications are FDA-approved for type 2 diabetes, weight management, or both:

• Semaglutide — Ozempic (diabetes), Wegovy (weight management), and Rybelsus (oral, diabetes).
• Liraglutide — Victoza (diabetes) and Saxenda (weight management).
• Tirzepatide — a dual GIP/GLP-1 receptor agonist — Mounjaro (diabetes) and Zepbound (weight management).
• Dulaglutide — Trulicity (type 2 diabetes only).

Of these, Wegovy and Zepbound are the versions specifically indicated for chronic weight management. The diabetes-indicated versions are sometimes used off-label for weight, though insurance coverage and savings-card eligibility rules differ for off-label use. For a side-by-side on individual agents, see our GLP-1 vs Ozempic comparison. Note that semaglutide is also FDA-approved for cardiovascular risk reduction in certain patients and, more recently, for metabolic dysfunction-associated steatohepatitis (MASH) — a reminder that these are serious medicines with expanding, closely studied indications.

A Word on Dosing (and Why It Isn’t in This Article)

These drugs are started low and increased gradually on a schedule your prescriber sets and adjusts for you, based on your response and how well you tolerate side effects. There is no safe one-size-fits-all starting dose or titration ladder to copy from an article, so this guide does not provide one. The milligram figures mentioned below are clinical-trial doses reported from published studies — they describe what researchers used, not a plan for you to follow. If you are prescribed a GLP-1, follow the exact directions from your prescriber and pharmacy, and never self-titrate, share pens, or adjust your dose on your own.

What the Trials Show

The STEP-1 trial of semaglutide (2.4 mg weekly in the trial), published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity but without diabetes. Participants on semaglutide lost an average of about 14.9 percent of body weight over 68 weeks, versus about 2.4 percent for placebo.

SURMOUNT-1 extended the category with tirzepatide, reporting average reductions of roughly 15, 19.5, and 22.5 percent across the trial’s dose arms. SURMOUNT-5 later showed tirzepatide outperforming semaglutide head-to-head. These figures are well beyond what any prior weight-loss drug class achieved, which helps explain the extraordinary clinical and commercial demand — and, again, they are trial results, not a dosing guide.

How Fast GLP-1 Weight Loss Happens

Trial data show meaningful weight loss beginning within the first month, accelerating during dose escalation, and continuing through roughly weeks 40 to 60 before slowing as the body approaches a new set point. In the first four weeks, average loss is often 2 to 4 percent of body weight; by weeks 12 to 16, about 6 to 10 percent; and by weeks 40 to 60, participants reach the plateau ranges of 15 to 22 percent.

Individual variability is substantial. Some patients lose 25 percent or more, while others lose 8 to 10 percent. Roughly 15 to 20 percent of trial participants qualified as low responders with less than 5 percent loss, and clinicians increasingly use response-based adjustments and switching between agents to address that — decisions made with a prescriber, not alone.

Boxed Warning and Contraindications

The most important safety point comes first. The GLP-1 class carries a boxed warning — the FDA’s strongest — for thyroid C-cell tumors. As MedlinePlus states for semaglutide, the medication “may increase the risk that you will develop thyroid gland tumors, including a type of thyroid cancer” called medullary thyroid carcinoma; this effect was seen in rodent studies, and whether it applies to humans is not established. Because of this, these drugs are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your prescriber about any thyroid history, and report symptoms such as a neck lump or swelling, hoarseness, trouble swallowing, or shortness of breath.

Side Effects to Expect

Gastrointestinal symptoms dominate the profile. Nausea affects roughly 30 to 40 percent of patients during dose escalation, though it usually eases over weeks as tolerance develops. Diarrhea, constipation, vomiting, indigestion, and abdominal pain are common. Most people manage these by eating smaller meals, avoiding fatty or greasy foods, staying hydrated, and letting the prescriber slow the titration if needed.

Less common but more serious risks include pancreatitis, gallbladder disease, acute kidney injury from dehydration (often secondary to vomiting or diarrhea), and low blood sugar in patients also taking insulin or a sulfonylurea. Seek prompt care for severe, persistent abdominal pain (which can signal pancreatitis or a gallbladder problem). See our tirzepatide side effects article and Ozempic pancreatitis guide for fuller coverage, and always report new or worrying symptoms to your prescriber.

Who Should Consider GLP-1 Therapy — and Who Should Not

FDA labeling limits weight-management GLP-1 use to adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). Candidates should be willing to pair medication with diet and activity changes, since every trial combined the drug with lifestyle counseling. These medicines are not for cosmetic weight loss: someone seeking to drop a few vanity pounds is not an appropriate candidate, and most prescribers will decline off-label use for that purpose.

Beyond the thyroid contraindications above, caution or avoidance applies with active pancreatitis, severe gastrointestinal disease, and pregnancy or breastfeeding (these drugs are generally stopped before a planned pregnancy). Patients with a history of depression or an eating disorder need careful evaluation, because appetite suppression can complicate both. This is a conversation for you and your clinician.

Stopping GLP-1 and Weight Regain

One of the most consistent findings in the trial literature is that weight regain occurs when GLP-1 therapy stops. The STEP-4 trial showed patients who switched from semaglutide to placebo regained roughly two-thirds of lost weight within 68 weeks; SURMOUNT-4 showed a similar pattern with tirzepatide.

This reflects the biology of obesity. These drugs treat the condition during use but do not cure the metabolic dysregulation that drives weight gain, so stopping tends to return the body toward its prior set point. For many patients, obesity-medicine specialists now frame GLP-1 therapy as a long-term or ongoing intervention rather than a short cycle — another reason the decision to start is a considered, prescriber-guided one.

Compounded and Counterfeit Products: A Caution

During the shortages of recent years, compounded versions of semaglutide and tirzepatide became widely available. That landscape has changed: the FDA removed semaglutide from its shortage list in early 2025 and tirzepatide’s shortage was declared resolved in late 2024, which wound down the legal basis for mass compounding of these drugs (specific enforcement timelines applied — verify the current status). The FDA stresses that compounded GLP-1 drugs “are not FDA approved,” meaning the agency has not reviewed them for safety, effectiveness, or quality, and it has received reports of adverse events “that may be related to dosing errors associated with compounded injectable semaglutide products.” The agency also warns about counterfeit products that may contain the wrong amount of active ingredient or none at all, and advises buying only FDA-approved medicines from state-licensed pharmacies. Be wary of “deep discounts,” products sold as “for research use only,” or sellers that do not require a prescription.

Cost and Access Realities

List prices are high — roughly $1,000 to $1,350 per month for the branded weight-management products, though what you actually pay depends heavily on coverage, savings cards, and manufacturer direct-to-patient options (prices change often; verify current figures). Commercial insurance coverage for weight loss remains inconsistent, and employer plans sometimes exclude GLP-1s for weight loss even when they cover them for diabetes. Medicare’s coverage of anti-obesity medications has been debated and is evolving through the Centers for Medicare & Medicaid Services, so confirm current policy. Manufacturer savings cards, patient-assistance programs, and self-pay options have become important access pathways. See our Wegovy cost guide and Zepbound cost without insurance.

Frequently Asked Questions

How much weight do people lose on GLP-1 drugs?

Trial averages show roughly 15 percent body-weight loss on semaglutide (Wegovy) at 68 weeks and up to about 22.5 percent on tirzepatide (Zepbound) at 72 weeks. Individual results vary — some lose more than 25 percent, others less than 10 percent.

How long does it take to see results on a GLP-1?

Most people notice reduced appetite within the first one to two weeks and measurable weight loss by about week four. Peak loss typically occurs around weeks 40 to 60, after which weight tends to stabilize.

Are GLP-1 drugs safe for long-term use?

Trial and real-world data over several years suggest they are generally safe for chronic use in appropriate patients, though very long-term data remain limited. Ongoing monitoring for gastrointestinal tolerance, thyroid symptoms, and gallbladder or pancreatic signs is part of responsible use.

What happens if you stop taking a GLP-1?

Most people regain a significant portion of lost weight. STEP-4 showed about two-thirds regained within 68 weeks after stopping semaglutide. Specialists generally treat these as long-term therapies.

Which GLP-1 is most effective for weight loss?

Based on SURMOUNT-5 head-to-head data, tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy). But individual response varies, and cost, coverage, and side-effect tolerance also drive the choice — which your prescriber makes with you.

The Bottom Line on GLP-1 Weight Loss

GLP-1 receptor agonists — and the dual-receptor tirzepatide — have meaningfully changed what medical obesity treatment can achieve. The trial data are strong, the mechanism is well understood, and average weight loss exceeds any prior drug class. The trade-offs are real: gastrointestinal side effects during titration, a class boxed warning for thyroid tumors, high cost, coverage barriers, and the likelihood of needing long-term treatment to maintain results. These are prescription-only medicines for obesity or overweight with complications — not cosmetic aids. If you are considering therapy, have a frank conversation with a qualified prescriber about eligibility, realistic expectations, safety, and how to combine medication with sustainable diet and activity changes.

Sources

• MedlinePlus (U.S. National Library of Medicine) — semaglutide: drug class, uses, boxed warning for thyroid tumors, side effects, contraindications, prescription-only status
• U.S. Food and Drug Administration (FDA) — approvals of Wegovy (semaglutide) and Zepbound (tirzepatide); “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”; counterfeit and dosing-error warnings; buy FDA-approved products from state-licensed pharmacies
• FDA drug shortage database — semaglutide removed from shortage list (Feb 2025); tirzepatide shortage resolved (late 2024) — verify current
• New England Journal of Medicine — STEP-1 (semaglutide) and SURMOUNT-1/-4/-5 and STEP-4 trial results
• Manufacturer prescribing information — Novo Nordisk (Wegovy) and Eli Lilly (Zepbound), including boxed warning and safety
• Centers for Medicare & Medicaid Services (CMS) — Medicare coverage of anti-obesity medications (policy evolving; verify current)